1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Visgeneer, Inc.

Visgeneer, Inc.

TTPEX:4197
8.30
TWD
-0.35
(-4.05%)
287.32MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.63
6.72
6.78
5.4
5.22
4.72
5.04
5.83
5.48
5.23
4.9
3.84
5.93
- -
Basic EPS, GAAP
1.07
0.67
0.73
0.01
-1.02
-1.06
-1.05
0.02
0.03
0.41
-0.65
-0.59
0.17
- -
Free Cash Flow per Basic Share
-0.72
-1.38
-4.33
0.62
-1.01
-0.18
-0.44
-0.48
0.15
1.39
0.42
-0.46
0.26
- -
Dividend per Share
- -
- -
0.27
0.24
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
9.53
10.25
10.52
10.33
9.31
8.26
7.2
7.14
7.25
7.66
7.01
6.42
6.6
6.37
Tangible Book Value per Share
9.14
9.91
10.23
10.07
9.04
8.05
7.07
7.07
7.22
7.63
6.99
6.41
6.59
6.37
Basic Weighted Avg Shares
30
30
31
30
30
30
30
30
30
30
30
30
30
30
Sales/Revenue/Turnover
200
203
207
163
158
143
152
176
165
158
148
116
179
- -
Operating Margin (%)
13.59
5.76
9.03
2.34
-15.2
-23.47
-20.69
-0.53
1.96
2.32
-0.65
-17.69
-3.02
- -
Depreciation Expense
7
6
7
21
20
21
21
20
16
19
17
14
13
- -
Net Income, GAAP
32
20
22
- -
-31
-32
-32
1
1
12
-20
-18
5
- -
Effective Tax Rate (%)
- -
- -
8.13
29.7
- -
- -
- -
- -
38.25
- -
- -
- -
- -
- -
Profit Margin (%)
16.1
9.97
10.77
0.23
-19.45
-22.37
-20.89
0.34
0.5
7.82
-13.24
-15.32
2.93
- -
Working Capital
192
198
92
197
187
173
159
145
153
171
123
107
109
97
LT Debt
- -
28
70
171
180
180
180
171
171
158
114
105
95
91
Total Equity
286
309
316
312
281
249
217
218
219
231
212
194
199
192
Return on Invested Capital (%)
- -
- -
4.2
0.55
- -
- -
- -
- -
0.49
0.85
- -
- -
2.19
- -
Return on Capital (%)
- -
- -
5.47
0.6
- -
- -
- -
- -
0.54
3.54
- -
- -
2.51
- -
Return on Common Equity (%)
12.02
6.8
7.13
0.12
-10.34
-12.03
-13.61
0.28
0.38
5.49
-8.85
-8.75
2.67
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
9
9
9
LT Borrowings
100
95
91
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
327
293
287

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
157
149
137
Cash, Cash Equivalents & STI
75
69
43
Accounts Receivable, Net
16
23
29
Inventories
58
51
58
Total Current Liabilities
47
41
40
Payables & Accruals
- -
- -
- -
ST Debt
9
9
9
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.3%
-1.62%
2.71%
Free Cash Flow
-3.49%
54.39%
-156.95%
Net Income, GAAP
-729.91%
208.74%
-129.6%
Sales/Revenue/Turnover
0.44%
3.22%
54.68%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
116
2025
- -
- -
179
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.59
2025
- -
- -
0.17
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Keng Shuo Tai
Full Time Employees
98
Sector
Health technology
Industry
Medical specialties
Address
No. 335, Zhonghua Road Hsinchu Taiwan 30094
IPO Date
Oct 24, 2013
Website
visgeneer.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Visgeneer Inc. is a Taiwan-based global innovator specializing in health solutions with core product lines including medical devices and cosmetics. The company manufactures and markets blood glucose, ketone, uric acid, and cholesterol monitoring systems with associated meters and test strips. In skincare, Visgeneer offers a broad range of products including functional masks, face care creams (night, day, wrinkle, whitening, repairing, exfoliating), body care lotions, physical and chemical sunscreens, cleansers (face wash, cleansing mousse, gel, shampoo, body wash), hand and foot care products, anti-acne treatments, female intimate cleaning lotions, skin and hair capsules, as well as customized skincare formulations. Additionally, the company develops cancer gene diagnostics using bioinformatics and biomolecular approaches with patented technologies in the EU and US, and provides contract manufacturing (OEM/ODM) services across its product lines. Visgeneer operates in more than 80 countries spanning six continents and maintains headquarters in Hsinchu City, Taiwan, having been founded in 2005. Recent strategic developments include deepening alliances and partnerships to strengthen sustainable growth, with increased investment in smart manufacturing and digitalization to enhance production and R&D capabilities. The company prioritizes vertical integration and controls sources of patented natural materials to develop unique skincare ingredients aimed at expanding its cosmeceutical market presence. Operationally, Visgeneer remains focused on improving sales and R&D service quality, targeting long-term customer relationships and broader application development based on existing technologies. However, it recently received an FDA warning letter regarding compliance with medical device marketing regulations in the U.S. market, highlighting ongoing regulatory challenges. Visgeneer continues to emphasize innovation in blood diagnostics, skincare, zeaxanthin products, and cancer gene testing, aiming to maintain its market leadership in these segments. The company trades under ticker 4197.TWO on the Taipei Exchange. This description reflects the latest available data on Visgeneer’s product portfolio and strategic initiatives as of late 2025.